Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021
 
NCT04426695
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID-19 mild to moderatesome concern
912/452 suggested
  • suggested 39 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
  • suggested 34 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
  • suggested 48 % increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).